The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer
Abstract Aberrant activation of Ras/Raf/mitogen-activated protein kinase (MAPK) signaling is frequently linked to metastatic prostate cancer (PCa); therefore, the characterization of modulators of this pathway